Vigil Neuroscience Inc VIGL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if VIGL is a good fit for your portfolio.
News
-
Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting
-
Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-
Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer
-
Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting
-
Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days
-
Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024
-
Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024
-
Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology Conference
Trading Information
- Previous Close Price
- $2.58
- Day Range
- $2.50–2.74
- 52-Week Range
- $2.50–11.11
- Bid/Ask
- $2.61 / $2.71
- Market Cap
- $101.85 Mil
- Volume/Avg
- 46,561 / 89,431
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 69
- Website
- https://www.vigilneuro.com
Comparables
Valuation
|
Metric
|
VIGL
|
CBAY
|
VRDN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.80 | 12.65 | 2.95 |
Price/Sales | — | 111.01 | 1,835.80 |
Price/Cash Flow | — | — | — |
Price/Earnings
VIGL
CBAY
VRDN
Financial Strength
|
Metric
|
VIGL
|
CBAY
|
VRDN
|
|---|---|---|---|
Quick Ratio | 10.24 | 10.70 | 17.93 |
Current Ratio | 10.45 | 10.96 | 18.26 |
Interest Coverage | — | −5.27 | −137.76 |
Quick Ratio
VIGL
CBAY
VRDN
Profitability
|
Metric
|
VIGL
|
CBAY
|
VRDN
|
|---|---|---|---|
Return on Assets (Normalized) | −42.47% | −30.06% | −42.76% |
Return on Equity (Normalized) | −48.11% | −51.97% | −82.42% |
Return on Invested Capital (Normalized) | −48.57% | −30.87% | −50.70% |
Return on Assets
VIGL
CBAY
VRDN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Xfjzzwzv | Ycfkz | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Jvmtbkqlf | Mxxsyg | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Xmkhgqd | Sdxscy | $97.8 Bil | |
MRNA
| Moderna Inc | Znhcjtq | Wlqr | $41.3 Bil | |
ARGX
| argenx SE ADR | Dnwsdkt | Wwzf | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Sqkmrqx | Kkns | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Lcdqvzpwy | Kqmhwk | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Zjwptpxk | Phvwkh | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Nbssrrhymc | Rqrrlpc | $12.5 Bil | |
INCY
| Incyte Corp | Ntkffkmc | Jglbny | $11.6 Bil |